Immunovaccine Inc, a vaccine development company, has signed a collaborative agreement with the Dana-Farber Cancer Institute, a principal teaching affiliate of the Harvard Medical School. The research collaboration involves formulating Dana-Farber’s HIV protein antigens in Immunovaccine’s DepoVax vaccine enhancement and delivery platform. The goal of this preclinical research is to establish whether this novel vaccine formulation will induce a stronger immune response.

“Dana-Farber is a leader in vaccine research and this collaboration presents an exciting opportunity to evaluate new antigens formulated in our DepoVax vaccine delivery platform," said Dr Marc Mansour, vice president of R&D at Immunovaccine. “We are hopeful this research will lead to new and expanded opportunities for our vaccine delivery platform.”

Dana-Farber Cancer Institute is a principal teaching affiliate of the Harvard Medical School and a federally designated Center for AIDS Research. It is also a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC) and designated comprehensive cancer center by the National Cancer Institute.

Immunovaccine is a clinical stage vaccine development company focused on the commercialization of its patented DepoVax vaccine delivery technology and product candidates.